July 7, 2020 -- Aboundbio has inked an agreement with SaudiVax for the production and clinical development of neutralizing antibodies against SARS-CoV-2.
The selected lead antibodies were selected by Aboundbio from a massive antibody library for ultra-specificity for SARS-CoV-2, as indicated by the absence of binding to over 5,300 proteins in the human cell surface proteome. Preclinical cell culture models did not induce antibody-dependent enhancement of infection and were effective at low doses in mouse and hamster models of SARS-CoV-2 infection.
Under the agreement, antibody production and clinical development for regulatory approval and commercialization will proceed in the Middle East and North Africa (MENA) and the Association of Southeast Asian Nations (ASEAN) regions by SaudiVax. This biotechnology company based in Saudi Arabia is a joint venture between UYC of Saudi Arabia and PnuVax of the U.S.
Copyright © 2020 scienceboard.net